



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 31/19, 9/00, 47/18</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/15597</b> <b>(43) International Publication Date:</b> 21 July 1994 (21.07.94)
<b>(21) International Application Number:</b> PCT/US94/00188 <b>(22) International Filing Date:</b> 6 January 1994 (06.01.94)  <b>(30) Priority Data:</b> 08/003,107 11 January 1993 (11.01.93) US  <b>(71) Applicant:</b> ALLERGAN, INC. [US/US]; 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534 (US).  <b>(72) Inventor:</b> WONG, Michelle, P.; 15662 Myrtle Avenue, Tustin, CA 92680 (US).  <b>(74) Agents:</b> BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> OPTHALMIC COMPOSITIONS COMPRISING BENZYL LAURYL DIMETHYLAMMONIUM CHLORIDE  <b>(57) Abstract</b>  An ophthalmic solution generally includes an ophthalmologically acceptable drug formulation incompatible with benzalkonium chloride and lauralkonium chloride present in an anti-microbially effective amount. The incompatibility of the ophthalmologically acceptable drug manifests itself by forming insoluble ion pairs with the benzalkonium chloride. It has been found that lauralkonium chloride which is the C <sub>12</sub> homolog of benzalkonium chloride is effective as a preservative without apparent interaction with the acidic ophthalmologically acceptable drug and formulations maintain their antimicrobial efficiency over periods of up to one year or more.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## OPHTHALMIC COMPOSITIONS COMPRISING BENZYL LAURYL DIMETHYLAMMONIUM CHLORIDE

5

The present invention generally relates to improved ophthalmic formulations and solutions and more particularly to improved preservative systems for ophthalmologically acceptable drug formulations which have an incompatibility with benzalkonium chloride. More specifically, the present invention pertains to the preservative for an anti-inflammatory drug such as sodium flurbiprofen (Ocufen®).

15

Ophthalmologically acceptable drug formulations generally contain effective compounds and a number of ophthalmologically acceptable excipients. Such excipients generally include solutions, ointments, and suspensions, etc. More specifically, such excipients include stabilizing agents, surfactants, buffering systems, chelating systems, viscosity agents, and, importantly, a preservative.

20

Ophthalmic formulations, understandably, must be sterile and if a multi-dose regime is intended, the formulation must be preserved with an effective antimicrobial agent.

25

As discussed in U.S. Patent No. 5,110,493, organo-mercurials have been used extensively as the preservatives in ophthalmic solutions. As reported in this reference, these compounds pose difficulties due to potential mercury toxicity as well as poor chemical stability.

-2-

Therefore, benzalkonium chloride, which is a quaternary ammonium compound, has been widely used in ophthalmic solutions. It is also well-known, however, that benzalkonium chloride is considered incompatible with anionic drugs, forming insoluble compounds which cause the solution to turn cloudy.

This is because of the fact that many acidic drug entities carry a negative charge at physiological pH. In fact, all acidic drug entities will carry a negative charge at all pH above their pKa.

In the case of benzalkonium chloride, which is a positively charged preservative, ion pairs can be formed with negatively charged drug compounds, forming an insoluble ion pair which causes the drug to precipitate out of solution. Concomitant with the removal of the drug from solution is the removal of benzalkonium chloride, thereby rendering this quaternary germicide incapable of performing its function as an antimicrobial agent.

Benzalkonium chloride is a mixture of alkyldimethylbenzylammonium chloride of the general formula as shown below in which R represents a mixture of the alkyls from  $C_8H_{17}$  to  $C_{18}H_{37}$

As hereinbefore noted, it is well-known that benzalkonium chloride is generally incompatible with anionic detergents or anionic drug compounds.

See U.S. Patent No. 5,110,493, and The Merck Index, 11th Edition, Merck & Co., Inc., 1989.

5           The present invention specifically relates to the discovery that a particular member of a group of compounds, generally known as benzalkonium chloride, exhibits properties totally different from other members of the group and different from the gross properties of the mixture known as benzalkonium chloride.

10           This discovery by the applicant must be taken in the context that all compositions are made of the same substances, retaining their fixed chemical properties. The elements are capable of an infinity of permutations, and selection of that group or element of a group which proves serviceable to a given need requires a high degree of originality.

15           This general premise relates to the invention at hand. The applicant has discovered that lauralkonium chloride, which is the  $C_{12}$  homolog of benzalkonium chloride, is compatible with acidic drug entities with apparently no insoluble ion pairs being formed therewith. This is contrary to the properties of the mixture of alkyldimethylbenzylammonium chloride,

20           known as benzalkonium chloride, which includes a mixture of the alkyls from  $C_8H_{17}$  to  $C_{18}H_{37}$ .

### SUMMARY OF THE INVENTION

25           An ophthalmic solution, in accordance with the present invention, generally includes an ophthalmologically acceptable drug formulation incompatible with benzalkonium chloride and lauralkonium chloride present in an antimicrobially effective amount. More specifically, flurbiprofen is an example of an acidic drug that forms an insoluble ion-

pair with benzalkonium chloride. However, when combined with lauralkonium chloride, no apparent insoluble ion pairs are formed.

5 More particularly, in accordance with the present invention, the ophthalmic solution may further include citric acid monohydrate, sodium citrate dihydrate, polyvinyl alcohol, edetate disodium dihydrate, sodium chloride, potassium chloride and water.

10 The amount of lauralkonium chloride is any antimicrobially effective amount and preferably may be up to about 0.005% by weight per volume of the solution, and the amount of sodium flurbiprofen may be present in any effective amount and preferably about 0.03% by weight per volume.

15 The combination of lauralkonium chloride is further emphasized in that it can be combined with an acidic ophthalmologically acceptable drug formulation having a negative charge at physiological pH, and further the fact that the acidic ophthalmologically acceptable drug is capable of forming an insoluble ion-pair with benzalkonium chloride, no apparent  
20 insoluble ion-pairs are produced when the drug is in combination with lauralkonium chloride, taken itself.

25 Further, the invention includes a method for preserving an acidic ophthalmologically acceptable drug solution, comprising adding to the ophthalmologically acceptable drug solution an antimicrobially effective amount of lauralkonium chloride.

### DETAILED DESCRIPTION

Flurbiprofen is a classic example of an acidic drug that forms an insoluble ion-pair with benzalkonium chloride. It has been discovered that  
5 this interaction (insoluble ion-pair formation) can be overcome by formulating the flurbiprofen with the  $C_{12}$  homolog of benzalkonium chloride and lauralkonium chloride.

The lauralkonium chloride utilized will comprise at least 95% and  
10 preferably about 97.8% of the  $C_{12}$  homolog, 1.5% of the  $C_{14}$  homolog, and 0.7% of the  $C_{16}$  homolog.

The following examples, illustrating the utility of lauralkonium chloride as opposed to benzalkonium chloride, include the preparation or  
15 compounding of flurbiprofen formulations as follows.

Compounding occurs in two parts:

Part 1: Disperse polyvinyl alcohol in rapidly stirring purified water  
20 and heat to 85°C. Maintain temperature and stirring for one hour to dissolve the polyvinyl alcohol.

Part 2: While mixing a bulk of purified water of at least 50% of the final lot volume, add edetate disodium, benzalkonium chloride or  
25 lauralkonium chloride, potassium chloride, sodium chloride, sodium citrate and citric acid allowing each to dissolve or mix well before adding the next. Adjust the pH to 6.4-6.6 with dilute sodium hydroxide and/or hydrochloric acid. Add sodium flurbiprofen to the bulk and mix well.

-6-

While mixing Part 2, add Part 1 and mix thoroughly. Adjust the pH to 6.4-6.6 with dilute sodium hydroxide and/or hydrochloric acid. Sterilize the lot by filtration (0.22 $\mu$ ) and aseptically fill units into pre-sterilized containers.

5

The benzalkonium chloride and the lauralkonium chloride utilized in the present examples were obtained from E.M. Industries, Inc. of Hawthorne, NY and Triple Crown Ammerica, Inc. of Perkasio, PA, respectively.

10

### Example

Table 1 shows the ingredients for Examples A and B, with the formulations being identical, except that Example A utilizes benzalkonium chloride and Example B utilizes lauralkonium chloride in the same amounts, i.e., 0.005%, by weight per volume.

15

**TABLE 1**

20

**OCULEN® FORMULATIONS**

25

30

Ingredient	Example A	Example B
	% w/v	% w/v
Sodium flurbiprofen	0.03	0.03
Benzalkonium chloride	0.005	-
Lauralkonium chloride	-	.005
Citric acid monohydrate USP	0.05	0.05
Sodium citrate dihydrate USP	0.45	0.45
Polyvinyl alcohol 20-90 Grade	1.4	1.4
Edetate disodium dihydrate USP	0.0127	0.0127



-7-

5

Sodium chloride USP	0.65	0.65
Potassium chloride USP	0.075	0.075
Purified water USP	qs to 100	qs to 100
Sodium hydroxide NF	pH 6.4 to 6.6	pH 6.4 to 6.6
Hydrochloric acid NF	pH 6.4 to 6.6	pH 6.4 to 6.6

10

Example A results in a cloudy solution with precipitate and loss of antimicrobial efficacy while Example B remains as a solution and the solution maintains its antimicrobial efficacy. Example A failed to pass the preservative effectiveness test as described in the British Pharmacopeia while Example B passes the British Pharmacopeia preservative effectiveness test.

15

20

In addition, the ability of lauralkonium chloride to stay in solution and to maintain its antimicrobial effectiveness as a function of time was also monitored. Table 2 shows the concentration of lauralkonium chloride in the formulation described in Example B. Table 3 shows the ability of lauralkonium chloride to maintain its antimicrobial efficacy over a period of up to one year or more.

TABLE 2

25

No. of Days	Lauralkonium chloride - ppm
13	46.0
32	46.0
75	45.8
115	45.0
192	47.7

-8-

370	48.2
-----	------

TABLE 3

No. of Days	Microbiology Results
13	Pass BP-88
370	Pass BP-88

Although there has been hereinabove described a specific ophthalmic solution and method in accordance with the present invention, for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. Accordingly, any and all modifications, variations, or equivalent arrangements which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.

**WHAT IS CLAIMED IS:**

1. An ophthalmic solution comprising:  
an ophthalmologically acceptable drug formulation  
incompatible with benzalkonium chloride; and  
a preservative consisting essentially of lauralkonium  
chloride and present in an antimicrobially effective amount.
2. The ophthalmic solution according to Claim 1 wherein said  
ophthalmologically acceptable drug formulation comprises sodium  
flurbiprofen.
3. The ophthalmic solution according to claim 2 further  
comprising citric acid monohydrate, sodium citrate dihydrate, polyvinyl  
alcohol, edetate disodium dihydrate, sodium chloride, potassium chloride,  
and water.
4. The ophthalmic solution according to Claims 1, 2 or 3  
wherein said lauralkonium chloride is present in an amount up to about  
0.005% by weight per volume of the solution.
5. The ophthalmic solution according to claim 2 or 3 wherein  
the sodium flurbiprofen is present in an amount up to about 0.03% by  
weight per volume of the solution and the lauralkonium chloride is present  
in an amount up to about 0.005% by volume of the solution.
6. An ophthalmic solution comprising:  
an acidic ophthalmologically acceptable drug  
formulation having a negative charge at physiological pH;  
and

5                                   a preservative consisting essentially of lauralkonium chloride and present in an antimicrobially effective amount.

7.       The ophthalmic solution according to Claim 6 wherein said ophthalmologically acceptable drug formulation comprises sodium flurbiprofen.

8.       The ophthalmic solution according to Claim 7 further comprising citric acid monohydrate, sodium citrate dihydrate, polyvinyl alcohol, edetate disodium dihydrate, sodium chloride, potassium chloride, and water.

9.       The ophthalmic solution according to Claims 6, 7 or 8 wherein said lauralkonium chloride is present in an amount up to about 0.005% by weight per volume of the solution.

10.      The ophthalmic solution according to Claim 7 or 8 wherein the sodium flurbiprofen is present in an amount up to about 0.03% by weight per volume of the solution and the lauralkonium chloride is present in an amount up to about 0.005% by volume of the solution.

11.      A method for preserving an acidic ophthalmically acceptable drug solution comprising adding to said ophthalmically acceptable drug solution an antimicrobially effective amount of lauralkonium chloride.

12.      An ophthalmic solution comprising:  
            an acidic ophthalmologically acceptable drug capable of forming an insoluble ion-pair with benzalkonium chloride;  
            and

-11-

5

a preservative consisting essentially of lauralkonium chloride and present in an antimicrobially effective amount.

## INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 94/00188

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K31/19 A61K9/00 A61K47/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 112, no. 16, 16 April 1990, Columbus, Ohio, US; abstract no. 145590h, see abstract & JP,A,01 246 227 (SANTEN PHARMACEUTICAL CO.,LTD.) 2 October 1989 ---	1,3,4,6, 8,9,11, 12
A	DATABASE WPI Week 8231, Derwent Publications Ltd., London, GB; AN 82-64749E (31) see abstract & JP,A,57 102 817 (KAKENYAKU KAKO KK) 26 June 1982 -----	2,5,7,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 April 1994

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/US 94/00188

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP-A-01246227	21-05-75	JP-A- 50058310 JP-B- 59016038 US-A- 4091167	21-05-75 12-04-84 23-05-78
JP-A-57102817	26-06-82	NONE	